Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹è´¢Áõ»óÀ» µ¿¹ÝÇÑ ºñÀü¸³¼±¾Ï ȯÀÚ¿¡¼­ ¿¬·É¿¡ µû¸¥ Àü¸³¼± ƯÀÌÇ׿øÀÇ »óÇÑÄ¡ Upper Limits for PSA in Relation to Age in Clinically Prostatic Cancer-free Patients with voiding Symptoms

´ëÇѺñ´¢±â°úÇÐȸÁö 1995³â 36±Ç 6È£ p.609 ~ 613
ÀÌâ¿ì, ±è´ö¹è,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌâ¿ì (  ) 
Ãæ³²´ëÇб³ °¡Á¤´ëÇÐ °¡Á¤±³À°°ú

±è´ö¹è (  ) 
Chungbuk National University

Abstract


We measured the concentration of serm PSA to define statistical upper limits for Psa in relation to age in 228 men without clinical evidence of prostatic cancer. We defined the cancer-free group as men with a PSA less than or equal to 2.5ng/ml
(ELSA-PSAR monoclonal immunoradiometric assay) and nonsuspicious digital rectal examination and those with an abnormality in either parameter underwent transrectal ultrasound and pathologically excluded prostatic cancer from the group by
transrectal
prostatic biopsy transurethral resection.
A total 252 men between 40 and 79 years of age entered the protocol, of whom 228 men satisfied our cancer-free criteria. There was a significant correlation between natural logarithm transformed PSA (In PSA) and age by linear regression analysis
(r=0.32, p=0.02) and age-specific uppe rlimits of Psa (mean+2SD) were 2.62ng/ml in the 40 to 49-year group, 3.45ng/ml in the 50 to 59-year group, 5.09ng/ml in 60 to 69-ye4ar group and 7.07ng/ml in the 70 to 79-year group.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS